Join the Oncology Brothers, Rahul and Rohit Gosain, in this insightful podcast episode as they dive into the world of small cell lung cancer with special guest Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson Cancer Center.

Key Points:

•⁠ ⁠The Adriatic study's impact on improving survival with Durvalumab in limited-stage disease.

•⁠ ⁠Treatment options for extensive-stage disease, including second-line therapies like Lurbinectedin and the recent approval of Tarlatamab.

•⁠ ⁠The significance of individualized treatment decisions and ongoing research in small cell lung cancer management.

In this episode, Dr. Singhi discusses the management of limited-stage small cell lung cancer, the impact of the recent Adriatic study on treatment approaches, and the use of immunotherapy in both limited and extensive-stage disease. The conversation also delves into the role of PCI, the use of Trilaciclib in extensive stage, and the recent FDA approval of Tarlatamab for small cell lung cancer.

Discover the latest advancements and treatment options for small cell lung cancer, including insights on second-line treatments, consolidation radiation, and the management of patients with driver mutations. Dr. Singhi also highlights the importance of patient advocacy groups like the Small Cell Smashers in providing support for individuals with small cell lung cancer.

Tune in to this episode for a comprehensive overview of the current treatment landscape for small cell lung cancer and gain valuable insights from Dr. Singhi's expertise in the field. Don't miss out on this informative discussion on the Oncology Brothers podcast!

Join Drs. Rohit Gosain and Rahul Gosain as they dive into the practice-changing updates from ASCO 2024 conference. In this episode, they are joined by Dr. Mark Lewis to cover key studies in GI malignancies from the conference.

In this episode, they discuss:

•⁠ ⁠The ESOPEC study comparing concurrent chemoradiation versus periop FLOT regimen for upper GI adenocarcinoma.

•⁠ ⁠The ARMANI trial on switch maintenance with ramucirumab plus paclitaxel.

•⁠ ⁠The TRANSMET trial exploring chemotherapy followed by liver transplantation for metastatic liver-confined colorectal cancer.

•⁠ ⁠The COLLISION trial comparing surgery versus ablation for small size colorectal liver metastatic disease.

•⁠ ⁠The COMMIT study looking at the use of atezolizumab with chemotherapy in first-line treatment for MSI high metastatic colorectal cancer.

These studies highlight the importance of biomarker testing and a multidisciplinary approach in the treatment of cancer.

Tune in to gain valuable insights from ASCO 2024 and stay informed about the latest advancements in oncology. Don't forget to check out their lung, GU, and breast cancer highlights from the conference as well.

Stay connected with the Oncology Brothers for more updates and discussions on the latest in the world of oncology. Thank you for tuning in!

Welcome to another insightful episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Toni Choueiri, a GU Medical Oncologist from Dana-Farber Cancer Institute, to discuss key abstracts from ASCO 2024.

They delve into topics such as the impact of the EV302 study on metastatic bladder cancer, the potential role of ctDNA as a biomarker in bladder cancer, real-world data on metastatic RCC, and the PSMA-4 study in prostate cancer. The discussion covers patient-reported outcomes, treatment strategies, and the evolving landscape of oncology care.

Tune in to gain valuable insights into the latest advancements in oncology and how they are shaping the standard of care for patients. Don't miss out on this engaging conversation with experts in the field. Subscribe to the Oncology Brothers podcast for more updates from the world of oncology.

Website: http://www.oncbrothers.com/

Twitter: https://twitter.com/oncbrothers

Contact us at info@oncbrothers.com